|
CICERO
Comparison of Intracoronary versus intravenous abciximab administration during Emergency Reperfusion Of ST-segment elevation myocardial infarction
Ongoing trial
 |
Author(s) |
Gu YL, Fokkema ML, Kampinga MA, de Smet BJGL, Tan ES, van den Heuvel AFM, Zijlstra F |
 |
Title(s) |
Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration |
|
Reference(s) |
Trials 2009;10:90 |
|
Disease |
MI |
|
Purpose |
To compare the effects on postprocedural myocardial perfusion of intracoronary bolus vs iv bolus administration of abciximab in patients with ST-segment elevation MI undergoing primary PCI with thrombus aspiration |
|
Study design |
Randomised, open, blinded-endpoint |
|
Follow-up |
Aim 30 days and 1 year |
|
Patients |
Aim 530 patients, aged ≥ 18 years, with ST-segment elevation MI, undergoing primary PCI with thrombus aspiration. Time since onset of symptoms: < 12 h |
|
Treatment regimen |
Abciximab, 0.25 mg/kg, intracoronary bolus or iv bolus |
|
Concomitant therapy |
Pretreatment with ASA, 500 mg, heparin, 5000 U, and clopidogrel, 600 mg. Nitroglycerin, 400 μg intracoronary during procedure, at the discretion of the physician
|
|
Results |
Not yet available |
|
|
|
